Immunotherapy plus chemotherapy for rectal cancer after chemoradiation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (dostarlimab) to standard chemotherapy after the usual chemoradiation helps treat locally advanced rectal cancer better than chemotherapy alone. Immunotherapy helps your immune system fight cancer cells, and may improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has not spread to distant parts of the body (stage 2 or 3).
- You have not had chemotherapy or radiation before.
- Your tumor is MSS or MSI-low, meaning it has normal DNA repair.
- You are in good general health (able to handle daily activities).
- Your blood counts and organ function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy with standard chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to see if this approach can improve outcomes for patients whose tumors have certain genetic features (pMMR or MSS).
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.